Noveome Biotherapeutics has dosed the first patient in a phase 2 trial of ST266 for persistent corneal epithelial defects, according to a press release.
Subjects in the open-label, multicenter clinical trial will receive four topical doses per day of ST266, a cell-free platform biologic that contains hundreds of proteins, for the 28-day duration of the study. Complete healing of the defect, determined by fluorescein dye, is the primary endpoint of the trial.
“We believe that ST266 has the potential to provide an innovative treatment option as a novel cell-free platform (Read more...)
Uncategorized